These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33157050)

  • 21. Comparative proteomic analysis uncovers potential biomarkers involved in the anticancer effect of Scutellarein in human gastric cancer cells.
    Saralamma VVG; Vetrivel P; Lee HJ; Kim SM; Ha SE; Murugesan R; Kim EH; Heo JD; Kim GS
    Oncol Rep; 2020 Sep; 44(3):939-958. PubMed ID: 32705238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer.
    Yeh CC; Hsu CH; Shao YY; Ho WC; Tsai MH; Feng WC; Chow LP
    Mol Cell Proteomics; 2015 Jun; 14(6):1527-45. PubMed ID: 25850433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic analysis of genotype-specific drug responses in cancer.
    Kim N; He N; Kim C; Zhang F; Lu Y; Yu Q; Stemke-Hale K; Greshock J; Wooster R; Yoon S; Mills GB
    Int J Cancer; 2012 Nov; 131(10):2456-64. PubMed ID: 22422301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
    Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
    Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
    Sun X; Song Q; He L; Yan L; Liu J; Zhang Q; Yu Q
    Mol Cancer Ther; 2016 Oct; 15(10):2508-2520. PubMed ID: 27458140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer.
    Ansari AA; Park I; Kim I; Park S; Ahn SM; Lee JL
    BMC Med Genomics; 2018 Oct; 11(1):88. PubMed ID: 30285760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling.
    Lescarbeau RM; Kaplan DL
    BMC Cancer; 2014 May; 14():325. PubMed ID: 24885093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies.
    Byron A; Bernhardt S; Ouine B; Cartier A; Macleod KG; Carragher NO; Sibut V; Korf U; Serrels B; de Koning L
    Sci Rep; 2020 Dec; 10(1):21985. PubMed ID: 33319783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells.
    Al Madhoun A; Haddad D; Al Tarrah M; Jacob S; Al-Ali W; Nizam R; Miranda L; Al-Rashed F; Sindhu S; Ahmad R; Bitar MS; Al-Mulla F
    Sci Rep; 2021 Jun; 11(1):11893. PubMed ID: 34088951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures.
    Federici G; Gao X; Slawek J; Arodz T; Shitaye A; Wulfkuhle JD; De Maria R; Liotta LA; Petricoin EF
    Mol Cancer Res; 2013 Jun; 11(6):676-85. PubMed ID: 23635402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance.
    Gao Y; Shen JK; Milane L; Hornicek FJ; Amiji MM; Duan Z
    Curr Med Chem; 2015; 22(11):1335-47. PubMed ID: 25666804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting a cell state common to triple-negative breast cancers.
    Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
    Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pooled screening for antiproliferative inhibitors of protein-protein interactions.
    Nim S; Jeon J; Corbi-Verge C; Seo MH; Ivarsson Y; Moffat J; Tarasova N; Kim PM
    Nat Chem Biol; 2016 Apr; 12(4):275-81. PubMed ID: 26900867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systems biology case study of ovarian cancer drug resistance.
    Chen JY; Shen C; Yan Z; Brown DP; Wang M
    Comput Syst Bioinformatics Conf; 2006; ():389-98. PubMed ID: 17369659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer.
    Yang T; Xu F; Sheng Y; Zhang W; Chen Y
    Anal Bioanal Chem; 2016 Oct; 408(26):7491-503. PubMed ID: 27510278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Stem Cells Therapeutic Target Database: The First Comprehensive Database for Therapeutic Targets of Cancer Stem Cells.
    Hu X; Cong Y; Luo HH; Wu S; Zhao LE; Liu Q; Yang Y
    Stem Cells Transl Med; 2017 Feb; 6(2):331-334. PubMed ID: 28191780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction.
    Berlow N; Haider S; Wan Q; Geltzeiler M; Davis LE; Keller C; Pal R
    IEEE/ACM Trans Comput Biol Bioinform; 2014; 11(6):995-1008. PubMed ID: 26357038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colony Lysate Arrays for Proteomic Profiling of Drug-Tolerant Persisters of Cancer Cell.
    Kume K; Nishizuka SS
    Anal Chem; 2017 Sep; 89(17):8626-8631. PubMed ID: 28753272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.